485 Utilization of adjuvant immunotherapy for stage IIB-IIC melanoma in US in the first year following FDA approval
Regular and Young Investigator Award Abstracts | November 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: A551-A551
10.1136/jitc-2025-sitc2025.0485